Novo Nordisk is additionally working with the US Food and Drug Administration (FDA) and is alerting the public that a counterfeit case of Ozempic® (semaglutide injection) pen was found in the US. The safety or efficacy of counterfeit products is unknown and they should not be used. Potential risks of taking a counterfeit medicine include serious adverse events.
For pictures and details to identify differences between an authentic FDA-approved Ozempic® pen in the US and counterfeit product, please click here.
To report counterfeit semaglutide products or any suspected Novo Nordisk counterfeit products, please call Novo Nordisk customer care at 1-800-727-6500 Monday through Friday from 8:30 AM to 6:00 PM ET.
If an individual is experiencing any side effects that may be related to the use of a counterfeit product, that person should immediately discontinue use and contact their healthcare provider, and is additionally encouraged to report the event to FDA’s MedWatch Safety Information and Adverse Event Reporting Program (1-800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, using the same customer care number (1-800-727-6500).
Websites selling counterfeit and/or tampered medicines should be reported to the FDA. Suspected counterfeit products may be reported to the FDA by calling the FDA’s Office of Criminal Investigations (OCI) at 1-800-551-3989 or a local OCI field office.